FCN-011

Fochon Pharmaceuticals, Ltd. · Phase 1 active Small molecule

FCN-011 is an investigational drug by Fochon Pharmaceuticals, Ltd., currently in Phase I and II trials for advanced solid tumors and NTRK fusion-positive advanced solid tumors. No FDA label exists yet.

At a glance

Generic name	FCN-011
Sponsor	Fochon Pharmaceuticals, Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FCN-011 CI brief — competitive landscape report
FCN-011 updates RSS · CI watch RSS
Fochon Pharmaceuticals, Ltd. portfolio CI